Browsing Tag
BridgeBio Pharma
3 posts
The rare disease opportunity behind BridgeBio Pharma’s BBP-418 breakthrough (NASDAQ: BBIO)
BridgeBio Pharma advances BBP-418 after Phase 3 muscular dystrophy results. Could the therapy unlock a major rare disease opportunity? Read the full analysis.
BridgeBio Pharma’s Acoramidis Phase 3 trial in ATTR-CM hits primary endpoint
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company specializing in genetic diseases and cancers, announced that the…
BridgeBio Pharma secures $299m in funding to accelerate genetic disease drug development
BridgeBio Pharma, a leading clinical-stage biopharma company specialising in treatments for genetic diseases, has raised $299.2 million in…